INSILICO MEDICINE CAYMAN TOPCO ANNOUNCES EXCLUSIVE GLOBAL LICENSE GRANTED TO LILLY FOR DEVELOPMENT, MANUFACTURING, AND MARKETING OF ORAL THERAPEUTICS IN PRECLINICAL STAGE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy LLY?
Source: moomoo
Grant Announcement: Insilico Medicine has received a worldwide exclusive license for the development, manufacturing, and commercialization of oral therapeutics.
Focus on Preclinical Development: The licensing agreement emphasizes the focus on preclinical development of these oral therapeutics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 897.000
Low
950.00
Averages
1192
High
1500
Current: 897.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
ELI LILLY - EBGLYSS MAINTAINS STABLE SAFETY PROFILE WITH NO NEW SAFETY CONCERNS IN ITS FIRST YEAR
Safety Profile Consistency: The safety profile of the product remains consistent, indicating reliability in its performance.
Lack of New Safety Signals: There have been no new safety signals reported in the first year of monitoring, suggesting ongoing safety assurance.
See More
ELI LILLY - EBGLYSS PROVIDES FOUR YEARS OF SUSTAINED DISEASE CONTROL FOR ATOPIC DERMATITIS
- Durable Disease Control: Eli Lilly has achieved four years of effective control over a specific disease, demonstrating the durability of their treatment approach.
- Focus on Dermatology: The advancements are particularly relevant in the field of dermatology, highlighting the company's commitment to addressing skin-related health issues.
See More
LILLY'S EBGLYSS (LEBRIKIZUMAB-LBKZ) PROVIDES LONG-LASTING DISEASE CONTROL FOR UP TO FOUR YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Treatment Duration: Patients with moderate-to-severe atopic dermatitis can receive up to four years of effective disease control.
Disease Management: The treatment aims to provide durable control of the condition, improving the quality of life for affected individuals.
See More
Lilly's EBGLYSS Shows Significant Four-Year Efficacy
- Efficacy Durability: In the ADlong Phase 3b study, nearly all patients treated with EBGLYSS achieved significant skin improvement (EASI-75) over four years, with 75% reaching near-complete skin clearance (EASI-90), indicating a transformative impact on the quality of life for eczema patients.
- Itch Relief: 78% of patients experienced significant itch relief (Pruritus NRS≤4) during treatment, which is crucial for enhancing daily living and mental health, demonstrating EBGLYSS's effectiveness in alleviating eczema symptoms.
- Steroid-Free Treatment: 80% of patients achieved results without the need for topical corticosteroids while on EBGLYSS, indicating the drug's ability to provide durable outcomes and reduce reliance on traditional therapies, thereby reshaping the treatment paradigm for eczema.
- Safety Profile: The safety of EBGLYSS in the first year of the ADlong study was consistent with known safety profiles, with no new safety signals observed, and the majority of adverse events were mild or moderate, reinforcing its potential as a first-line biologic treatment.
See More
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
ELI LILLY - EBGLYSS MAINTAINS STABLE SAFETY PROFILE WITH NO NEW SAFETY CONCERNS IN ITS FIRST YEAR
Safety Profile Consistency: The safety profile of the product remains consistent, indicating reliability in its performance.
Lack of New Safety Signals: There have been no new safety signals reported in the first year of monitoring, suggesting ongoing safety assurance.
See More
ELI LILLY - EBGLYSS PROVIDES FOUR YEARS OF SUSTAINED DISEASE CONTROL FOR ATOPIC DERMATITIS
- Durable Disease Control: Eli Lilly has achieved four years of effective control over a specific disease, demonstrating the durability of their treatment approach.
- Focus on Dermatology: The advancements are particularly relevant in the field of dermatology, highlighting the company's commitment to addressing skin-related health issues.
See More
LILLY'S EBGLYSS (LEBRIKIZUMAB-LBKZ) PROVIDES LONG-LASTING DISEASE CONTROL FOR UP TO FOUR YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Treatment Duration: Patients with moderate-to-severe atopic dermatitis can receive up to four years of effective disease control.
Disease Management: The treatment aims to provide durable control of the condition, improving the quality of life for affected individuals.
See More
Lilly's EBGLYSS Shows Significant Four-Year Efficacy
- Efficacy Durability: In the ADlong Phase 3b study, nearly all patients treated with EBGLYSS achieved significant skin improvement (EASI-75) over four years, with 75% reaching near-complete skin clearance (EASI-90), indicating a transformative impact on the quality of life for eczema patients.
- Itch Relief: 78% of patients experienced significant itch relief (Pruritus NRS≤4) during treatment, which is crucial for enhancing daily living and mental health, demonstrating EBGLYSS's effectiveness in alleviating eczema symptoms.
- Steroid-Free Treatment: 80% of patients achieved results without the need for topical corticosteroids while on EBGLYSS, indicating the drug's ability to provide durable outcomes and reduce reliance on traditional therapies, thereby reshaping the treatment paradigm for eczema.
- Safety Profile: The safety of EBGLYSS in the first year of the ADlong study was consistent with known safety profiles, with no new safety signals observed, and the majority of adverse events were mild or moderate, reinforcing its potential as a first-line biologic treatment.
See More
